8-K: Ainos Inc. Reports Second Quarter 2024 Financial Results and Clinical Trial Progress

Ainos, Inc. announced its Q2 2024 financial results, highlighting progress in clinical trials for feline chronic gingivostomatitis (FCGS) and advancements in its AI-powered point-of-care testing technology.

Summary

• Ainos, Inc. reported its financial results for the second quarter of 2024, ending June 30th.
• The company's revenue was nominal at $0, compared to $28,555 in the same period last year, due to the cessation of COVID-19 antigen rapid test kit sales.
• Cost of revenues decreased to $25,373 from $55,817 year-over-year, due to lower sales volume.
• Gross profit was negative $25,373, an improvement from negative $27,262 in Q2 2023.
• Total operating expenses increased to $3,023,636 from $2,289,336 year-over-year, driven by increased R&D and SG&A costs.
• R&D expenses rose to $1,978,756, up from $1,671,187 in the same period last year.
• SG&A expenses increased to $1,044,880 from $618,149 year-over-year.
• Net loss attributable to common stock shareholders was $3,195,022, compared to $2,349,727 in Q2 2023.
• The company had cash and cash equivalents of $8,014,098 as of June 30, 2024, compared to $1,885,628 at the end of 2023.
• Ainos raised $9 million through a convertible note financing in May 2024.
• The company prepaid a senior secured convertible note in August 2024 and believes it has a financial runway for more than 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and a strong cash position, the financial results show a significant decline in revenue and increased losses. The company's future outlook is positive, but the current financial performance is concerning.

Positives

• The company has made meaningful progress in initiating a clinical study for treating feline chronic gingivostomatitis (FCGS).
• Ainos has a strong financial position with over $8 million in cash and cash equivalents.
• The company has secured a financial runway for more than 12 months.
• The company is advancing its AI Nose technology with the Next-Gen Ainos Flora.
• Ainos is actively seeking out-licensing opportunities for its VELDONA human drug candidates.
• The company has successfully tested its Ainos Flora VOC POCT device in clinical trials.

Negatives

• Revenues were nominal in the second quarter of 2024, at $0, compared to $28,555 in the same period of 2023.
• The company experienced a negative gross profit of $25,373 in Q2 2024.
• Total operating expenses increased to $3,023,636 in Q2 2024, compared to $2,289,336 in Q2 2023.
• The net loss attributable to common stock shareholders was $3,195,022 in Q2 2024, compared to $2,349,727 in Q2 2023.

Risks

• The company's dependence on projected revenues from the sale of current or future products is a risk.
• Ainos has a limited cash and a history of losses.
• The company's ability to achieve profitability is uncertain.
• There is a risk that the company may not be able to raise additional capital to continue product development.
• The company faces intense competition and rapidly advancing technology in its industry.
• There are risks associated with the cost of production and sales potential of the products.
• The company is subject to potential cybersecurity attacks and increased costs related to cybersecurity.
• There are risks associated with the ability to obtain and maintain regulatory approval of Ainos product candidates.
• Delays in completing the development and commercialization of the company's current and future product candidates could result in increased costs.

Future Outlook

Ainos is focused on fast-tracking VELDONA commercialization, progressing its AI Nose technology, and seeking out-licensing opportunities for its human drug candidates. The company believes it has a financial runway for more than 12 months.

Management Comments

• Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, 'We've made meaningful progress in initiating a clinical study for treating feline chronic gingivostomatitis (FCGS).'
• Chun-Hsien (Eddy) Tsai stated, 'Our core strategy for this oral low-dose interferon alpha (IFN) formulation remains focused on fast-tracking VELDONA commercialization by identifying optimal opportunities and effectively utilizing our resources.'
• Chun-Hsien (Eddy) Tsai noted, 'I see significant market opportunity in FCGS, a cat oral disease with 0.7-10% estimated prevalence rate, where pet parents are facing few treatment options.'
• Christopher Lee, Chief Financial Officer of Ainos, commented, 'We had some deferred revenues from product sales in the quarter.'
• Christopher Lee stated, 'We have continued to be capital efficient, as demonstrated by our prudent management of operating expenses, excluding depreciation, amortization, and stock-based compensation.'
• Christopher Lee commented, 'After prepaying a senior secured convertible note in August 2024, we believe we maintain a financial runway for more than 12 months.'

Industry Context

The announcement highlights Ainos' strategic shift towards drug development in the animal health market, capitalizing on the growing trend of pet owners prioritizing animal health. The company is also leveraging its AI-powered point-of-care testing technology to address unmet needs in both human and animal health.

Comparison to Industry Standards

• Ainos' shift towards drug development for animal health, specifically targeting FCGS, aligns with the growing trend of pharmaceutical companies expanding into the veterinary market, similar to companies like Zoetis and Elanco.
• The company's focus on AI-powered point-of-care testing is comparable to companies like Abbott and Roche, which are also investing in advanced diagnostic technologies.
• The development of VELDONA, a low-dose interferon therapeutic, is similar to other companies exploring interferon-based treatments, such as Biogen and Merck, although Ainos is focusing on different applications.
• The company's financial results, with nominal revenue and increased operating expenses, are not uncommon for early-stage biotech companies focused on R&D, similar to companies like Novavax and Moderna in their early stages.

Stakeholder Impact

• Shareholders may be concerned about the company's increased losses and nominal revenue.
• Employees may be impacted by the company's strategic shift and focus on drug development.
• Customers may benefit from the company's new products and services in the future.
• Suppliers may be affected by the company's changing product focus.
• Creditors may be interested in the company's financial stability and ability to repay debts.

Next Steps

• Ainos will continue to progress its clinical study for treating feline chronic gingivostomatitis (FCGS).
• The company will advance the development of its AI Nose technology, with the Next-Gen Ainos Flora targeting design completion in Q3 and clinical trial kickoff in Q4.
• Ainos will actively seek out-licensing opportunities for VELDONA human drug candidates.
• The company aims to complete the enrollment of 30 subjects for the FCGS clinical trial by the end of 2024.
• Ainos plans to finalize the trial report for the FCGS clinical study in Q1 2025.

Key Dates

Keywords

Ainos, VELDONA, AI Nose, POCT, FCGS, Clinical Trial, Interferon, Animal Health, Drug Development, Financial Results